Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update
BJ Schneider, J Naidoo, BD Santomasso… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …
recommended management of immune-related adverse events (irAEs) in patients treated …
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice …
JR Brahmer, C Lacchetti, BJ Schneider… - Journal of Clinical …, 2018 - ascopubs.org
Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …
recommended management of immune-related adverse events in patients treated with …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) …
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …
therapy may vary substantially in their clinical presentation, including natural history …
Immune-related adverse events of immune checkpoint inhibitors: a brief review
G Myers - Current oncology, 2018 - mdpi.com
Immune checkpoint inhibitors (ICIS) such as inhibitors of CTLA-4, PD-1, and PD-L1, given as
monotherapy or combination therapy have emerged as effective treatment options for …
monotherapy or combination therapy have emerged as effective treatment options for …
[HTML][HTML] Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines
S Trinh, A Le, S Gowani, NM La-Beck - Asia-Pacific journal of oncology …, 2019 - Elsevier
Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and
programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint …
programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
JR Brahmer, H Abu-Sbeih, PA Ascierto… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …
cancers. While these immunotherapies have improved patient outcomes in many clinical …
[HTML][HTML] Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
KL Reynolds, S Arora, RK Elayavilli… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving
outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and …
outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and …
Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors
Importance Toxic effects of conventional chemotherapy and molecularly targeted cancer
therapies are generally well defined and occur at predictable points. By contrast, owing to …
therapies are generally well defined and occur at predictable points. By contrast, owing to …
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
X Zhou, Z Yao, H Yang, N Liang, X Zhang, F Zhang - BMC medicine, 2020 - Springer
Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity …
I Puzanov, A Diab, K Abdallah, CO Bingham… - … for immunotherapy of …, 2017 - Springer
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …
immune-based therapies, including the widely used class of agents known as immune …
相关搜索
- checkpoint inhibitors adverse events
- practice guideline adverse events
- immunotherapy of cancer adverse events
- checkpoint inhibitors meta analysis
- meta analysis adverse events
- practice guideline checkpoint inhibitor
- checkpoint inhibitors consensus recommendations
- checkpoint inhibitors managing toxicities
- checkpoint inhibitors timing in patients
- consensus definitions adverse events
- event occurrence timing in patients
- immunotherapy of cancer checkpoint inhibitor
- checkpoint inhibitors variation in the assessment
- american society adverse events
- checkpoint inhibitors event occurrence
- checkpoint inhibitors patients with cancer